Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
98 studies found for:    HER2 and imaging
Show Display Options
Rank Status Study
1 Completed Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients
Conditions: Breast Neoplasms;   Secondary;   HER2 Positive Carcinoma of Breast
Intervention: Drug: Zr89-trastuzumab
2 Recruiting IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Procedure: Molecular imaging
3 Completed PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Radiation: PET Imaging With Cu-64 Labeled Trastuzumab
4 Unknown  HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025
Condition: HER2-positive Breast Cancer
Intervention: Other: Radiolabeled [68Ga]ABY-025
5 Completed 89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition
Condition: Breast Cancer
Intervention: Other: Imaging with 89Zr-trastuzumab PET
6 Recruiting HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1
Condition: HER-2 Positive Breast Cancer
Interventions: Drug: T-DM1;   Procedure: 89Zr-trastuzumab
7 Recruiting Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
Conditions: Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: bevacizumab;   Drug: trastuzumab;   Procedure: magnetic resonance imaging;   Procedure: therapeutic conventional surgery
8 Terminated Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)
Condition: Breast Cancer
Intervention: Other: 111In-Pertuzumab + SPECT-CT
9 Completed Biodistribution and Dosimetry of Serial PET Imaging With Ga-68 Labeled F(ab') 2- Trastuzumab
Condition: Solid Tumors
Intervention: Radiation: PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab
10 Recruiting 89ZrTrastuzumab Breast Imaging With Positron Emission Tomography
Condition: Breast Cancer
Interventions: Drug: 89Zr-Trastuzumab Human Dosimetry and Safety;   Drug: HER2 Positive Lesion Detection and Safety
11 Completed 111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer
Conditions: Breast Cancer;   Prostate Cancer;   Lung Cancer;   Colon Cancer
Intervention: Drug: 111Indium CHX-A DTPA trastuzumab
12 Completed FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Fluorothymidine F-18;   Procedure: Positron Emission Tomography;   Other: Laboratory Biomarker Analysis
13 Recruiting Copper (Cu) 64-DOTA-Trastuzumab PET Imaging in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer
Conditions: HER2 Positive Breast Carcinoma;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Radiation: Copper Cu 64-DOTA-Trastuzumab;   Other: Laboratory Biomarker Analysis;   Biological: Pertuzumab;   Procedure: Positron Emission Tomography;   Procedure: Therapeutic Conventional Surgery;   Biological: Trastuzumab
14 Recruiting Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients
Conditions: Healthy Volunteers;   Breast Cancer
Intervention: Biological: [131I]-SGMIB Anti-HER2 VHH1
15 Recruiting ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA
Condition: HER2 Negative Breast Carcinoma Expressing CEA
Intervention: Drug: TF2 - 68 Ga-IMP-288:
16 Not yet recruiting Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer
Condition: HER-2 Positive Breast Cancer
Interventions: Other: Cardiac Magnetic Resonance Imaging (CMR);   Other: Echocardiogram (ECHO)
17 Active, not recruiting Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification
Condition: Breast Cancer
Interventions: Drug: Carvedilol;   Other: placebo
18 Unknown  Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer
Conditions: Breast Cancer;   Metastatic Cancer
Interventions: Biological: trastuzumab;   Drug: chemotherapy;   Procedure: magnetic resonance imaging
19 Completed Exploratory Study of Breast Cancer With ABY025
Condition: Breast Cancer
Intervention: Drug: 111-In-ABY-025
20 Completed PET Study of Breast Cancer Patients Using [68Ga]ABY-025
Condition: Breast Cancer
Intervention: Drug: [68Ga]ABY-025

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years